Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
2期
提前终止
NCT05167409
| 适应症 | Microsatellite Stable Metastatic Colorectal Cancer |
|---|
| 分期 | 2期 |
|---|
| 申办方 | University of Colorado, Denver |
|---|
| 状态 | 提前终止 |
|---|
| 受试者人数 | 19 人 |
|---|
| 干预（药物） | Evorpacept (ALX148), Cetuximab, Pembrolizumab |
|---|
| 开始日期 | 2022年7月28日 |
|---|
| 完成日期 | 2024年10月30日 |
|---|
| 结果公布日 | 2026年7月22日 |
|---|
摘要
This Phase 2 clinical study will evaluate evorpacept (ALX148) in combination with cetuximab and pembrolizumab for refractory microsatellite stable metastatic colorectal cancer
Objective Response Rate (ORR)
The duration of time during which tumor assessments were performed for each individual patient. Per protocol, assessments will continue until disease progression. The latest assessment was performed at Cycle 21, Day 15 (14.5 mo after informed consent) · Participants
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 10 mg/kg Weekly | 0 Participants |
|---|
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 15 mg/kg Weekly | 0 Participants |
|---|
| Experimental: Stage 2: Expansion Cohort Using Recommended Dose (RD) of Evorpacept | 1 Participants |
|---|
Determine the Recommended Dose (RD) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab
During the safety run-in, each patient must have completed at least the 1st cycle (3 weeks) of treatment. · Participants
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 10 mg/kg Weekly | 0 Participants |
|---|
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 15 mg/kg Weekly | 1 Participants |
|---|
| Experimental: Stage 2: Expansion Cohort Using Recommended Dose (RD) of Evorpacept | 0 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。